

JAK inhibitor selection in challenging scenarios of myelofibrosis: a review

Pankit Vachhani,¹ Ruben Mesa,² John Mascarenhas,³ Raajit Rampal,⁴ Stephen T. Oh,⁵ Alessandro Maria Vannucchi,⁶ Maria Laura Fox,⁷ Francesca Palandri,⁸ Francesco Passamonti,⁹ Jean-Jacques Kiladjian,¹⁰ Mahshid Azimi,¹¹ Claire Harrison¹² and Prithviraj Bose¹³

¹Division of Hematology and Oncology, Department of Medicine, University of Alabama, Birmingham, AL, USA; ²Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA; ³Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ⁴Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁵Division of Hematology, Washington University School of Medicine, St Louis, MO, USA; ⁶Department of Clinical and Experimental Medicine, University of Florence and Careggi Hospital, Florence, Italy; ⁷Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain; ⁸Department of Medical and Surgical Sciences, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," Bologna, Italy; ⁹Department of Oncology and Hematology-Oncology, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ¹⁰Department of Clinical Pharmacology, Paris Cité University, INSERM, Paris, France; ¹¹GSK plc, Philadelphia, PA, USA; ¹²Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK and ¹³Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Correspondence: P. Vachhani
pvachhani@uabmc.edu

Received: July 9, 2025.
Accepted: November 13, 2025.
Early view: November 20, 2025.

<https://doi.org/10.3324/haematol.2025.288654>


©2026 Ferrata Storti Foundation
Published under a CC BY-NC license



Supplemental information

Supplemental Figure 1

Definitions of ruxolitinib failure from the modified Delphi panel consensus study¹



References

1. Mascarenhas J, Nguyen H, Saunders A, et al. Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: a modified Delphi panel consensus study. *Future Oncol.* 2023;19(11):763-773